Compare Cassava Sciences Inc (FLNA) vs Schlumberger NV (SLB) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

SLB trades at $47.54, up 0.38% with neutral technical signals. The company shows solid fundamentals with a P/E of 20.95 and net margin of 9.26%, though revenue dipped slightly in 2025. Recent strategic alliances with Liberty Energy for data center power and major EPC contracts with Eni highlight growth initiatives. Analyst consensus is strongly bullish with an $63 price target, representing 32% upside potential from current levels.

The outlook remains positive given strong contract wins and diversification into data center infrastructure. However, risks include oil price volatility and execution challenges in new ventures. With 85% of analysts rating it Buy and consistent earnings beats, SLB presents a compelling opportunity for investors seeking energy technology exposure, though macroeconomic headwinds require monitoring.